Abstract Number: 0970 • ACR Convergence 2021
Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes
Background/Purpose: Skin inflammation and photosensitivity are common manifestations of cutaneous (CLE) and systemic lupus erythematosus (SLE), yet the mechanisms underlying heightened cell death and epidermal…Abstract Number: 1020 • ACR Convergence 2020
Relationship Between Skin-related Quality of Life, Psychosocial Stress, and Race in Cutaneous Lupus Erythematosus
Background/Purpose: Chronic stress may trigger or exacerbate physiologic pathways that worsen individual health and wellbeing. Stress is associated with the development and progression of skin…Abstract Number: 088 • 2020 Pediatric Rheumatology Symposium
Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting
Background/Purpose: Exposure to sunlight has been implicated as a major contributing factor in the pathogenesis of systemic lupus erythematosus (SLE) and juvenile dermatomyositis (JDM). Despite…Abstract Number: 65 • 2019 ACR/ARP Annual Meeting
CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE
Background/Purpose: T cells are an important contributor the pathogenesis of SLE and its various end organ manifestations. Thus, they present themselves as potential therapeutic targets;…Abstract Number: 702 • 2019 ACR/ARP Annual Meeting
Seasonality of Cutaneous and Systemic Flares in Adults and Children in the Einstein Lupus Cohort
Background/Purpose: Ultra violet light (UV) exposure has been implicated as a major contributor to pathogenesis and flares in lupus. While some studies have looked at…Abstract Number: 861 • 2019 ACR/ARP Annual Meeting
Cutaneous Lupus Erythematosus Disease Area & Severity Index (CLASI) Demonstrates Thresholds for Detection of Treatment Response in a Phase-2, Placebo-Controlled Trial of Ustekinumab in SLE
Background/Purpose: Ustekinumab (UST), an anti-IL-12/23 p40 monoclonal antibody, showed significantly greater improvement at week (wk) 24 compared with placebo (PBO) in Systemic Lupus Erythematosus Disease…Abstract Number: 1111 • 2019 ACR/ARP Annual Meeting
Lupus Teledematology: A Pilot Project to Evaluate the Plausibility of a Rapid Access Dermatology Service for Lupus Patients
Background/Purpose: Clinicians have been increasingly using social media sites professionally. Platforms such as WhatsApp ® could be a potentially effective tool in teledermatology for rapid diagnosis and/or…Abstract Number: 2030 • 2019 ACR/ARP Annual Meeting
Staphylococcus Aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by Interferon-Mediated Barrier Disruption
Background/Purpose: Background/Purpose: Cutaneous inflammation is recurrent in systemic lupus erythematosus (SLE) and is often triggered by exposure to ultraviolet B (UVB) light. Type I interferons…Abstract Number: 2031 • 2019 ACR/ARP Annual Meeting
Interferon Alpha Promotes Caspase-Dependent Apoptosis Independently of Reactive Oxygen Species in Ultraviolet B-Exposed Keratinocytes
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by increased sensitivity to ultraviolet radiation (UVR). UVR can trigger cutaneous and systemic disease fares,…Abstract Number: 2037 • 2019 ACR/ARP Annual Meeting
Understanding Langerhans Cell ADAM17 Levels in Systemic Lupus Erythematosus: Potential Contributor to Photosensitivity
Background/Purpose: Photosensitivity resulting in inflammatory skin lesions is a hallmark of cutaneous lupus. Lesions can be disfiguring and have a negative impact on patients’ quality…Abstract Number: 2897 • 2019 ACR/ARP Annual Meeting
Increased CD69+ Tissue-resident Memory T (TRM) Cells and STAT3 Expression in Cutaneous Lupus Erythematosus Patients Recalcitrant to Antimalarials
Background/Purpose: Cutaneous lupus erythematosus (CLE) is an autoimmune disease with various subsets and clinical manifestations. T lymphocytes are the predominant cell type found in lesional…Abstract Number: 2100 • 2018 ACR/ARHP Annual Meeting
Topical Endocannabinoid Administration Protects MRL-Lpr/Lpr Mice from Cutaneous Lupus Erythematosus
Background/Purpose: Cutaneous lupus erythematosus (CLE) affects ~75% of SLE patients and has a profound impact on quality of life. While the morbidity from CLE is…Abstract Number: 725 • 2018 ACR/ARHP Annual Meeting
Preliminary Population-Based Incidence and Prevalence Estimates of Primary Discoid Lupus and Cutaneous Lupus Erythematosus from the Manhattan Lupus Surveillance Program
Background/Purpose: The extant epidemiologic data of primary discoid lupus erythematosus (DLE) and primary cutaneous lupus erythematosus (CLE) remains limited with few published estimates for the…Abstract Number: 752 • 2016 ACR/ARHP Annual Meeting
Anti-Ro Positivity Is a Predictor of Responsiveness to Topical Steroids or Hydroxychloroquine in Patients with Discoid but Not Subacute Cutaneous Lupus
Background/Purpose: Cutaneous lupus erythematosus (CLE) lesions are difficult to treat and medications are often chosen based only on provider experience. Thus, we chose to assess…Abstract Number: 1397 • 2016 ACR/ARHP Annual Meeting
Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index (CLASI) and Skindex-29 with Cutaneous Childhood Lupus Erythematosus (cSLE)
Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index (CLASI) and Skindex-29 with Cutaneous Childhood Lupus Erythematosus (cSLE) *Ashwaq AlEÕed, **Nora Al Mutairi ,…